Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

e three weeks. Brostallicin was escalated from 5 to 7 to 9 mg/m2 with a fixed dose of cDDP of 75 mg/m2. To review the poster for more detailed information, please go to http://www.CTICSeattle.com.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumors models. Brostallicin binds covalently to DNA within the DNA minor groove interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that

is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's 'context of vulnerability.' Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs -- the 'context of vulnerability'.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer mo
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... company that provides innovative genetic analysis solutions, and ... esoteric laboratory services in the United States ... prenatal testing patents and applications. "We have ... and patient care, and we welcome the opportunity to ...
(Date:7/29/2014)... a new way of manufacturing microstructured surfaces that ... self-assembly of carbon nanotubes, could exhibit a variety ... and strength, or the ability to repel water ... that mechanical forces can be used to direct ... we can independently control the mechanical properties ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4A new way to make microstructured surfaces 2
... Processes and products based on,biomass and industrial ... in a wide range of applications such as,bioplastics. ... industrial,biotechnology in Germany will be held at the ... 2008) in Chicago, Illinois.,The panel runs from 10:45am ...
... be Produced in Changzhou Hi-Tech ... District, ... inactivated rabies animal vaccines was recently launched in,Changzhou National High-tech District, ... team of leading overseas scientists. It is,reported that it is the ...
... 25 Arpida Ltd.,(SWX: ARPN) today announced that Dr ... Officer. Dr Jurgen Raths commands extensive,knowledge in the commercialisation ... and has successfully built and lead the European,Critical Care ... for many years., At the Annual General Meeting ...
Cached Biology Technology:World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment 2Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou 2Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou 3Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 2Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 3Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 4
(Date:7/30/2014)... Progress in developing robust therapies for spinal cord injury ... has been slow. A great deal has been learned ... factors and the environmental factors that regulate axon growth, ... resulted in clinically available therapeutics. Prof. Lemmon and his ... therapeutic bottleneck has many root causes, but a consensus ...
(Date:7/30/2014)... online today in the journal Scientific Reports , ... and Auroop Ganguly found that while global temperature is ... extremes. For instance, while each year,s average hottest and ... tend to fall within a wider range of potential ... observed. This means that even as overall temperatures rise, ...
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2Menu secrets that can make you slim by design 2
... 2010 New evidence that genetics play a significant role ... can do everything right and still give birth too soon. ... for Maternal-Fetal Medicine (SMFM) meeting -- The Pregnancy Meeting -- ... fetus can make them susceptible to an inflammatory response that ...
... Himalayan mountains are thinning is not disputed. However, few ... causes. Lawrence Berkeley National Laboratory scientist Surabi Menon set ... blamed culpritgreenhouse gases, such as carbon dioxidefrom other particles ... Menon and her collaborators found that airborne black carbon ...
... could predict which patients with the lung-scarring disease known as ... an indicator that could one day influence their treatment, according ... Their findings, published online last week in PLoS One ... tissue, suggesting that IPF is in fact an immunologic disease. ...
Cached Biology News:New research shows genes of pregnant women and their fetuses can increase the risk of preterm labor 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Test could predict which idiopathic pulmonary fibrosis patients will become severely ill 2
...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
...
... Signets Xylene Resistant (X/R) Red ... Chromogen, X/R Red Activator and X/R ... reacts with alkaline phosphatase to produce ... mounted. ,Kit Contains:, , Buffer, ...
Biology Products: